Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prourokinase recombinant - Tasly Pharmaceutical

Next Previous
X
Search
Drug Profile

Prourokinase recombinant - Tasly Pharmaceutical

Alternative Names: B-1140; B-1448; Pro-UK; PUK; Recombinant human pro-urokinase; Recombinant human urokinase - Tasly Pharmaceuticals; rhPro-UK; rhPro-uk - Tasly Pharmaceuticals

Latest Information Update: 07 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tasly Pharmaceuticals, Inc.
  • Class Anti-ischaemics; Plasminogen activator enzymes; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Preregistration Pulmonary embolism
  • Phase III Stroke

Most Recent Events

  • 14 Mar 2024 Tasly Biopharmaceuticals completes the phase III PROST-2 trial in Stroke in China (IV, Infusion) (NCT05700591)
  • 29 Jan 2023 Tasly Biopharmaceuticals initiates a phase III PROST-2 trial for Stroke in China (IV, Infusion) (NCT05700591)
  • 26 Jan 2023 Tasly Biopharmaceuticals plans a phase III PROST-2 trial for Stroke (IV, Infusion) in February 2023 (NCT05700591)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top